Neurocrine Biosciences

Update in progress

NBIX (NasdaqGS)

Company RatingAt Risk
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Neurocrine Biosciences discovers, develops, and commercializes medicines for neurological, psychiatric, endocrine, and immunological disorders in the United States and globally. Approved products include INGREZZA for tardive dyskinesia and Huntington’s chorea; Orilissa for endometriosis; Oriahnn for uterine fibroids; and CRENESSITY, ALKINDI, and Efmody for congenital adrenal hyperplasia. The company has multiple clinical programs and collaborations with Takeda, AbbVie, Sanofi, Xenon, Voyager, Nxera, and Tanabe. Based in San Diego, founded in 1992.

Company score

Sentiment: -1.47; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.02; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -2.05; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -1.18; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.85; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -1.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive